Simulations Plus (SLP) Akcie Kurz
Simulations Plus Kurz
Za posledních 19 let vzrostly tržby Simulations Plus o 14,7 % ročně a dosáhly 79,18 Mil. USD. Zisk na akcii rostl o 15,0 % ročně za posledních 18 let. U Simulations Plus je čistá marže -81,7 % dolů oproti 21,1 % před několika lety. Při dnešní ceně vychází dividendový výnos zhruba na 0,97 %. Výplatní poměr je kolem 37 % zisku. Konsenzuální 12měsíční cílová cena pro Simulations Plus je 18,50 USD, asi nad cenu o 0,0 %. Z 12 analytiků jich 0 doporučuje nákup — celkový konsenzus je Prodat.
Cena akcie Simulations Plus
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Simulations Plus a analýza akcií
Nejčastější otázky týkající se akcie Simulations Plus
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Analytici aktuálně stanovují průměrnou cílovou cenu 18,50 USD pro akcii Simulations Plus (medián: 18,50 USD), tedy +0,0 % vůči poslední ceně. Konsensus vychází z 12 hodnocení analytiků.
12 analytiků aktuálně hodnotí akcii Simulations Plus: 0 doporučuje koupit, 7 držet a 5 prodat. Pro rok 2026 analytici očekávají u Simulations Plus tržby 81,80 Mil. USD a zisk na akcii 0,82 USD.
Při aktuálním kurzu se akcie Simulations Plus obchoduje za 16,48 EUR (18,50 USD).
Akcie Simulations Plus (SLP) je kótována na 1 burzách, mimo jiné: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
Tržby očekávané za Simulations Plus činí 81,80 Mil. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Simulations Plus činí 16,48 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Simulations Plus je aktuálně 22,69. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Simulations Plus.
Poměr ceny k tržbám (P/S) Simulations Plus je aktuálně 4,57. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Simulations Plus.
Score kvality pro Simulations Plus je 3/10.
ISIN Simulations Plus je US8292141053. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Simulations Plus je 924294. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Simulations Plus je SLP. Symbol tickeru se používá k obchodování akcií Simulations Plus na burze.
Simulations Plus akcie
Simulations Plus Peer Group
Simulations Plus Ticker
Simulations Plus FIGI
Všechny fundamentální údaje o Simulations Plus v podrobné analýze
Naše analýzy akcií společnosti Simulations Plus zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Simulations Plus. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: